Abstract. The unique features of monoclonal antibodies (specificity, effectiveness, purity and unlimited reproducibility) make them ideal tools for the specific treatment of all kind of diseases. The third generation of monoclonal antibodies for the treatment of human diseases will be, after murine and "humanised' murine immunoglobulins, fully human antibodies. The best source of human monoclonal antibodies are the antibody pools of cancer patients themselves with the best technique for generating them being conventional human hybridoma technology. This technique, will generate human monoclonal antibodies which will not only define important new targets on cancerous tissue, but will also provide the necessary therapeutic human antibodies in the fight against cancer.
Introduction
Hybridoma technology began mid-60's after Littlefield described a selection method for fused fibroblast cells [1, 2] . Approximately ten years later, Köhler and Milstein used this somatic hybridisation and selection technique and fused a lymphocyte from an immunised mouse to a myeloma cell to produce the first murine antibody of defined specificity [3] . This milestone experiment has had enormous consequences for all fields of scientific and commercial activity [4, 5] .
Monoclonal antibodies are now widely accepted as supportive, or even alternative, therapeutic agents for the treatment of specific human medical disorders, with approximately 75 antibodies either in clinical trials or having already received approval for human use [6] [7] [8] [9] [10] [11] [12] . However, a closer inspection of the current preclinical and clinical trials with monoclonal antibodies, reveals three striking facts. First, only a small fraction (about 20%) of the trials concern antibodies directed against malignancies. Moreover, only four antibodies have so far been approved for human therapeutic use (Campath , Herceptin , Rituximab , Gemtuzumab ), in contrast to eight antibodies for other diseases [6, 10] .
Second, most of the targets for anti-cancer antibodies are differentiation antigens, like CD20, CD52, EGFreceptor, which are not really tumour-specific [6, 7, 10, 13, 14] .
Third, in cancer studies none of the antibodies are of human origin, compared to about 5% human antibodies in other clinical trials [6, 10] .
Hybridoma technology, like no other modern approach (including vaccination and gene therapy), holds the highest expectations for cancer treatment, with the added belief that human antibodies will become of greater significance in cancer therapy. Bearing this point in mind, it is surprising that after 25 years of institutional and industrial research that progress in developing better therapeutic antibodies for tumour-specific targets has been so slow.
The IgM trauma
In 1977, two years after Köhler and Milstein produced the first murine hybridoma antibody, the first human immunoglobulin was generated by infection of a human B-cell with Epstein-Barr-virus [15] . Three years later the first human-human hybridoma secreting a human immunoglobulin was described [16] .
Compared to the progress achieved with murine antibodies, human hybridoma technology developed only slowly. However after the initial technical problems had been solved, like the limited availability of proper fusion partners and human lymphocytes, a series of promising advances were made, including the generation of a huge panel of human antibodies against malignancies and other diseases [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] .
Interestingly, almost 100% of the tumour-reacting antibodies, which were isolated from cancer patients, were pentameric IgM antibodies. These IgM antibodies also exhibited characteristics common to conventional antisera, like cross-reactivity or poly-specificity and low affinity. The antibodies also reacted not only with membrane-bound structures, but also with cytoplasmic and nuclear proteins, and with carbohydrate structures and glycolipids [31] [32] [33] [34] [35] [36] . Subsequent sequence analysis revealed that these human IgM antibodies with anti-tumour activity were part of the innate (natural) immunity, germ-line coded and not affinity maturated [37] [38] [39] .
Per definition, monoclonal antibodies had to be mono-specific, with the epitope representing a defined protein. Immunity was equivalent to adaptation, affinity maturation, mutation and memory and, in contrast to mono-specific, mature antibodies generated by immunisation of mice, these cross-reacting "natural" IgM antibodies were termed "non-specific". In addition to the numerous intellectual and technical problems, experimental data also suggested that IgM molecules do not pass the blood-tissue endothelial barrier and cannot penetrate tumour tissue [40, 41] .
The unfortunate consequence of the problems which surrounded human antibody technology was that with beginning of the 90's the interest in the classical human hybridoma-technology decreased dramatically. Only a handful of research groups continued to work with human monoclonal antibodies,almost all of which were isolated directly from cancer patients [31, [42] [43] [44] [45] [46] [47] [48] .
It was therefore not surprising that interest in the use of murine antibodies as therapeutic agents was again favoured by many research groups. However, in an attempt to decrease the immunogenicity of the murine antibodies in patients, a lot of effort was invested in developing approaches to make murine antibodies appear more 'human-like' to a patient's immune system. To achieve this, murine antibodies were 'humanised' through the exchanging of murine immunoglobulin sequences with those of human origin [49] [50] [51] .
Importantly, interest in the use of fully human monoclonal antibodies as therapeutic agents did not disappear completely. However, advances in scientific technology meant that instead of following the classic approach of immortalising human lymphocytes for the production of human antibodies, more sophisticated methods were established. Genes for human antibodies were now being cloned and expressed in bacteria (phage display libraries) or transfected into mice (HuMAbmouse or Xenomouse) [52] [53] [54] [55] [56] [57] . Through the in vitro screening of the phage display libraries and the immunisation of transgenic mice, it should be possible to produce not only human antibodies of high specificity and affinity, but it should also be possible to define new antibody specificities.
State of affairs
The donor species and specificity of monoclonal antibodies are important for the success of clinical trials. Murine antibodies are both antigenic and immunogeneic in humans and therefore induce a strong humananti-mouse-antibody (HAMA) immune response. The HAMA effect decreases the half-life of murine antibodies in humans which necessitates the need for increased doses and concentrations of murine antibody to achieve therapeutic levels. In an attempt to improve murine antibodies to either lessen or overcome the HAMA effect, genetically engineered antibodies comprising portions of murine and human antibody gene fragments, referred to as "chimeric" and "humanised" antibodies, were developed. Such chimeric (30% murine) or humanised (under 10% murine) antibodies are more "human-like", but they still retain varying amounts of mouse antibody protein sequence and, accordingly, may continue to trigger the HAMA response. Once the process of "humanisation" of murine antibodies is complete, the genetically engineered and remodeled antibody gene must first be expressed in a recombinant cell line appropriate for antibody manufacture. However, the combination of murine and human antibody gene fragments can result in a final chimeric or humanised antibody product the structure of which differs from the original murine antibody, leading to a decrease in specificity or a loss in affinity [50, 58] .
By using phage display techniques, human single chain antibodies or antibody fragments are coupled to phages and expressed in bacteria. The resulting libraries are screened with specific antigens and the positive reacting antibody chains are then converted (engineered) to produce a complete immunoglobulin. The engineered immunoglobulins are then inserted into a standard immunoglobulin expression vector and "fully" human antibodies, which are then ready for assessment as therapeutic tools, can be produced [52, 53, 57, 59] .
Using the Xenomouse technology, a substantial majority of human antibody genes have been introduced into murine hosts, the advantage being that murine antibody genes remain silent. In this approach genetically reconstituted mice are first immunised after which murine lymphocytes are immortalised, and human immunoglobulin producing hybrids selected. "Human" antibodies of murine origin are produced without the need for subsequent engineering, unlike for the phage display technique described above [54] [55] [56] .
All these techniques have one thing in common in that they offer ideal opportunities for the production of humanised or human monoclonal IgG antibodies of high specificity and affinity and which minimise adverse patient immune responses (HAMA) to the monoclonal antibody.
Surprisingly, however, the majority of antibodies that are either approved, or are in late stage development, for use against solid human tumours are all of murine origin. The antibodies, either chimeric or humanised murine antibodies, are nearly all directed against molecules of the same EGF-R family, or structurally related tyrosin kinase receptors, known as erbB receptors: Abgenix and Genentech with Herceptin anti-HER2/neu for mammary carcinoma [60] , ImClone and Merck with Cetuximab (anti-EGF R) for carcinoma of the colon, head and neck [61] and Medarex with MDX-447 (bi-specific anti-CD64 and EGF-R) and MDX-H210 (bi-specifc anti-CD64 and anti-HER2/neu) for carcinoma of the head, neck, prostate and kidney [62] [63] [64] . An additional phase III trial with a humanised murine antibody (OvaRex ) directed against CA 125 [65] , a receptor detected 20 years ago, is being conducted by Altarex as a therapeutic agent for ovarian cancer [66, 67] .
Despite the availability of new techniques which have improved the antibodies for therapeutic use against human carcinomas the search for new targets for antibodies in the fight against cancer has been slow. After 25 years of xeno-immunisations with all manner of tumour cells and extracts, we have now hundreds of murine antibodies against hundreds of differentiation antigens, but only a handful of antibodies against structures which are really tumour-specific.
Furthermore, the immunisation of "humanised" mice, or the screening of human antibody phage display libraries with whole cells or cell extracts generate immune responses against the major differentiation antigens whereas minor modifications, for example in carbohydrates structures, are not detected. These techniques described above are ideal for the generation of human antibodies against defined viral and bacterial antigens, and probably auto-antigens, but not in the search for new antibodies against important, and as yet undetected, human carcinoma epitopes.
Nature's defence
"The major question is not why cancer occurs, but why it occurs so infrequently?" (J.D. Watson) [68] : The immunity of an organism can be divided into an innate (natural) and an adapted (acquired) response, or into an existing immunity and one that has to be trained [69] [70] [71] . The innate immunity (also referred to as "unspecific immunity") consists of natural killer (NK) cells, dendritic and mast cells, macrophages and antibody producing B-cells [69, [72] [73] [74] [75] [76] [77] [78] . This system can distinguish between self and non-self and is responsible for the first specific immune response directed against bacteria, viruses and also malignant cells [79] [80] [81] . To guarantee a fast reaction, the response is T-cell independent, which means that antigen-presentation by T-cells is not required [82, 83] . This innate immune system has enough genetic variability to cover a very broad spectrum of foreign antigens which ensures that we are not overcome by the multitude of infections or malignant cells that challenge the average human body over the period of a standard lifetime.
The cells which are involved in innate immunity recognize specific pattern instead of specific single structures. These conservative pattern are expressed independently from mutational events [79] . To recognize such pattern, the immune-competent cells use specific sets of germ-line coded receptors which belong to distinct protein families [70, 74, 79] . Based on and initiated by the innate immunity, the acquired or "specific" immunity then becomes involved. This T-cell dependent defence requires a period of in which specifically tai- lored weapons are developed to combat the challenge and reaches a maximum response several days after the initial contact with the antigen. The result of the Tcell dependent immune response is at the humoral level with mature B-cells secreting mutated and highly specific IgG and long-lasting memory cells [84, 85] . The "natural B-cell" pool, consisting of CD5+ positive lymphocytes, produces antibodies that principally belong to the IgM class [86] [87] [88] . These IgM antibodies are germ-line coded and do not increase their variability by mutational events and maturation [37] [38] [39] . The number of possible binding sites is therefore limited and each antibody has to cover a broader spectrum of different specific antigens such as specific pattern of carbohydrates etc. [31] [32] [33] [34] [35] 47, 48, 88] . Natural antibodies are therefore "oligo-specific" and not "non-specific", as they are often referred to in the literature. However, the price for oligo-reactivity is a lower affinity to each specific antigen. Reflecting all data on humoral response to malignant cells, there are striking similarities between humoral defence against bacterial and malignant cells suggesting that nature's defence against transformed cells is based on innate immune mechanisms and is not the result of an antigen-induced maturation process. 
Human Hybridoma Technology

Real human antibodies
Antibodies that define new tumour-related molecules can be readily isolated from the sera of cancer patients [89, 90] . Whilst the antisera have only limited therapeutical advantages, they can however be used to isolate and characterise new tumour-related structures. The tumour-reactive antibodies can be purified and then used for the construction or isolation of human antibodies using techniques like phage display or the HuMAbmouse systems, described above.
The classic or conventional approach to hybridoma technology of immortalising human lymphocytes by somatic hybridisation solves the problem of species and specificity of monoclonal antibodies for therapeutic use. In this technique, the first screening following immortalisation of the human lymphocyte is made against the autologous tumour and in the second step, the corresponding epitope on the tumour cells is identified with the same tumour-specific antibody (see Fig. 1 ).
By using this approach, we have been able to characterise a series of human monoclonal antibodies, which are useful for therapy and diagnosis, in addition to two new receptors. Figure 2 shows the receptor identified by the human monoclonal antibody SC-1 [31, 37, 47, 91, 92] . The structure identified on the membrane of stomach carcinoma cells is a modified version of DAF (Decay acceleration factor), also known as CD55. Figure 3 shows the receptor for the human monoclonal antibody PAM-1 (formerly 103/51). This molecule belongs to the family of cysteine-rich FGF receptors and is a variant of CFR-1 (cysteine-rich fibroblast growth factor receptor 1) [38, 45, 48] . CFR-1/PAM-1 is expressed on nearly all epithelial cancer cells and on the precursor cells of neoplasms.
It is therefore possible, to produce useful human monoclonal IgM antibodies which define new tumourrelated structures with a single experimental approach, making this technique superior to phage display or humAbmice
IgM handling
Cross-reactivity of germ-line IgMs is commonly observed in biochemical and immunohistochemical procedures [31, [33] [34] [35] . Therefore, the handling of natural IgMs in experimental systems requires specific adaptations to compensate for their characteristics. First of all, the primary selection of human antibodies from cancer patients is a pre-requisite for success. The initial search for membrane epitopes always begin with binding assays with living cells, (e.g. FACS analysis, functional assays). This approach guarantees the recognition of a membrane-bound epitope on the tumour cells and staining on autologous tissue enables selection for tumour-specificity.
Specificity analysis of antibodies in immunohistochemical studies provides vital information, in addition to the specific reactivity of the antibody, regarding cross-reactivities with repetitive structures such as muscle or connective, glandular tissue (mucine in parietal cells) and squamous epithelial cells. Background staining levels following binding of the second anti-human antibodies to immunoglobulins in the tissue, in addition to non-specific binding or stickiness of the first antibody over the Fc-part, can be reduced by pre-incubation of the sections with proteins or antibodies. Monoclonal and polyclonal human IgMs should be used in each experiment as controls and their reactivity should be substracted from the study antibody to provide the specific activity (see Figs 4 and 5) .
Receptor analysis using western blots with protein extracts usually identifies several reactive proteins, membranous, cytoplasmic and nuclear structures [31, 32, 48] . Fractionation of the extracts and saturation with large amounts of protein can reduce non-specific binding and provide specific bands.
In general, it is important to determine the impact of antibody cross-reactivities with regards to the study goal. However, should a membrane reacting IgM antibody also react with an epitope in the cytoplasm or nucleus, this should, in general, not limit its use as a likely therapeutic agent. However, thorough acute animal toxicity studies should be conducted to exclude the possibility of antibody cross-reactivity posing a danger for therapeutic use.
Breaking the dogma
The ideal mouse tumour model should mimic the pathobiologic, genetic, aetiologic and therapeutic characteristics of its human counterpart and faithfully reproduce all aspects of tumourgenesis. Validation parameters should not only include histopathology, molecular/genetic changes and stages of progression, but also therapeutic responses [93, 94] . Mouse cancer models, in which the murine host has been transplanted with human tumours, have been useful in screening some potential chemotherapeutic and chemopreventive agents. Recently, mouse models with spontaneous tumours have been "constructed" in an attempt to mimic more closely human tumourgenesis but even with this approach, no mouse tumour model will mimic every aspect of its human counterpart and there remains considerable scepticisms about the value of such models for drug development [95] [96] [97] [98] .
In addition, human proteins induce a humoral immune response in all mice, regardless of whether the murine species exhibits wild-type characteristics or is mutated, e.g. athymic mice [99] [100] [101] . This leads not only to a rapid and unpredictable clearance of human antibodies in the murine host, but also to a high variability in experimental evaluations. The only reliable and reproducible investigation in murine hosts involving either "humanised" or human antibodies is the acute toxicity assay. All other experimental approaches may give a hint to antibody activity in patients, but they are not a serious method for quality and quantity analysis of human antibodies.
Despite this, animal experiments are still used for the evaluation of human antibodies. However, one of the most prominent arguments against the use of native IgM molecules for therapy is that a pentameric IgM molecule with a mass of approximately 1 Mill kDa cannot pass the blood-tissue endothelial barrier and does not penetrate surrounding tissue [40, 41] . This dogma is mainly based on observations in experimental animal systems, where mice, or other animals, were inoculated with human tumour cells, mostly via the subcutanous route, and the subsequent diffusion and penetration patterns of radiolabeled antibodies was measured. Generally, a highly specific tumour targeting was only possible with small antibody fragments, whereas molecules with a size of monomeric immunoglobulins remained predominantly in the bloodstream, did not cross the endothelial barriers, and were rapidly cleared [102] [103] [104] [105] .
However, morphological and structural analysis of human, and even experimentally induced solid mouse tumours, demonstrate that the blood vessels in tumours are a mix of normal and abnormal vessels and are not comparable to vessels in healthy tissue [106, 107] . The vascular permeability of tumour tissue has been shown to be heterogeneous and the ultrastructure is dynamic which can be modulated by the microenvironment, e.g. inflammatory processes [108] [109] [110] . Tumour microvessels are in general thin walled, chaotically arranged, and lack innervation [105] with a greater permeability for macromolecules than the normal vessels [106, [111] [112] [113] [114] [115] .
After having left the blood vessels, macromolecules have to pass the extracellular matrix and tumour inter- stitium before reaching the tumour. These compartments are, under normal circumstances, physiological barriers and do not favour transport of even specific macromolecules. However, the tumour interstitium is also characterised by large intestinal spaces with the absence of a well defined functional network and changing interstitial fluid pressures, all of which are factors that can support the movement of macromolecules to the tumour interstitium [116] [117] [118] .
Importantly, soluble IgM and IgA antibodies are associated with a protein, called J-chain, which binds antibody monomers and creates more effective pentameric and dimeric antibodies. The J-chain is also responsible for transportation of these large molecules through barriers where it binds to specific polymeric immunoglobulin receptors on epithelial (and endothelial?) cells with the resulting transcellular transport of antibodies through the processes of transcytosis and osmocytosis [119] [120] [121] .
In summary, experimental tumours in mice cannot be compared with human neoplasms and almost all results obtained, concerning human antibody activity, specificity and transport, are of only limited value. In addition, the majority of tumour targeting experiments have been performed with antibodies directed against structures that are not tumour-specific at all, such as CEA, TAG-72, EPG-2, 17-1A etc. [105] . One must therefore consider the possibility that the experimental data, which discredits larger molecules, are the result of poor specificity and passive diffusion of the antibodies and not of specific targeting.
However, the best argument against the "pentameric IgM antibodies do not cross the endothelial barrier" dogma, is the example of human monoclonal IgM antibody SC-1 which has been used in a clinical trial for patients presenting with carcinoma of the stomach. In this study, patients diagnosed with primary stomach tumours received a single dose of SC-1 antibody intravenously. Two days after the injection, the apoptotic effect of the antibody was visible in primary tumours and metastases (Fig. 6) [37, 122] . This proves that pentameric IgM molecules are able to leave the circulation, cross the endothelia and matrices to reach the interstitium and the tumour, and to specifically kill tumour cells in vivo (see also [91, 92, 123] ).
Denouement
It is widely accepted that third generation, fully human antibodies are likely to offer the most effective treatment for numerous human diseases for the near future. These state-of-the-art antibodies, produced either by phage technology or transgenic mice will be used for the treatment of both immune and infectious diseases. However, for the treatment of cancer, the best (and only?) source of fully human antibodies are the cancer patients themselves.
After 15 years of experience with human antibody technology and human IgMs, the majority of the technical problems concerning low affinity and crossreactivity of human IgM antibodies have been solved. It is now possible to use these human monoclonal IgM antibodies for both diagnostic and therapeutic studies. Furthermore, the use of human antibodies, produced using conventional hybridoma technology, is the best and most rapid method for the definition of new tumour targets. IgM antibodies may prove to be the best weapon against malignancies that nature itself created. However, if we are unable to overcome our prejudices against the use of IgM antibodies as therapeutic agents, it is likely that we will have overlooked one of the best weapons in the fight against cancer.
